Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Quanterix Are Climbing This Morning

By Jason Hawthorne – Oct 12, 2021 at 12:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Regulators are helping accelerate an early test for Alzheimer's disease.

What happened

Shares of life sciences company Quanterix (QTRX -0.59%) are up 14% as of 11:30 a.m. EDT today after the Food and Drug Administration granted breakthrough status to its blood test for a biomarker of Alzheimer's disease.

So what

Tau is a protein that stabilizes microtubules in the neurons of the central nervous system. In Alzheimer's disease, tau detaches from the microtubules and tangles. This blocks communication between synapses. Elevated levels of tau are typically found in the cerebral spinal fluid of patients with neurodegenerative diseases, as well as severe brain injuries. Phospho-tau 181 is a specific protein that is more strongly associated with the disease than overall tau levels. The breakthrough device designation is the FDA's way of allowing manufacturers to try and expedite products that offer a potentially more effective treatment or diagnosis for life-threatening diseases. 

A person paints at a table with flowers on it while a caregiver watches over their shoulder.

Image source: Getty Images.

The test from Quanterix -- the Simoa p-Tau 181 -- is currently approved for research use only and is intended to measure the concentration of the protein in blood. That aids in earlier detection of the disease with a goal of providing patients more time to access potential therapies.

Now what

The Quanterix test isn't stand-alone. The company intends it to be used in conjunction with other diagnostic tools. Still, it could be an important next step in limiting the impact of the disease. And there could be others on the horizon.

Findings presented at last year's Alzheimer's Association International Conference and published in the Journal of the American Medical Association showed that the disease could also be detected through the biomarker p-tau217 as much as 20 years before the onset of cognitive decline. Further, the study showed blood tests were more accurate than expensive and intrusive methods like spinal taps and brain scans.  

The relationship with p-tau217 was validated in Eli Lilly's recent data related to its Alzheimer's drug candidate donanemab. Quanterix management hinted on the most recent earnings call that it was interested in the development, signaling a test for p-tau217 could be in the works.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Quanterix Corporation Stock Quote
Quanterix Corporation
$13.38 (-0.59%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.